
NavDx®
Optimizing HPV+ Cancer Care




The NavDx® Test Result: Surveillance

This easy-to-interpret, actionable test result provides valuable information that informs clinical decisions.

The highly sensitive NavDx test finds and measures tumor tissue modified viral HPV DNA (TTMV-HPV DNA) in a patient's blood sample. TTMV-HPV DNA is a biomarker that is specific to HPV-driven cancers, and it is found only in the blood of people with active HPV-driven cancer, such as oropharyngeal or anal cancers. NavDx analyzes fragments of TTMV-HPV DNA released by tumor cells into the blood and provides a TTMV Score, reflective of the normalized TTMV-HPV DNA fragments/ml of plasma.[1]

The TTMV-HPV DNA biomarker is also specific to the HPV genotype involved in the patient's cancer. The test detects HPV-16, HPV-18, HPV-31, HPV-33, and HPV-35. NavDx is not an HPV test; it does not detect active HPV infection that is unrelated to an HPV+ cancer.

Once a specimen arrives at our laboratory, test results are typically available within 7 business days. Reports are delivered based on your reporting preferences. If you're signed up on our Provider Portal, you will receive a notification when results are ready.



Each NavDx report includes:

- **A** Patient information
- **B** Provider information
- **C** Quick summary of test findings: TTMV-HPV DNA status and TTMV Score
- **D** Clinical details: Summarizes the patient's key clinical information at the time the test was ordered
- **E** The graph: Sequentially plots the patient's TTMV Score history
- **F** Test results & interpretation: Includes TTMV Score, Risk Score Interpretation, tumor HPV genotype, and a brief qualitative, written interpretation of the test result.

1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058.

CareDx

© 2026 Naveris (now part of CareDx) 21 Hickory Drive, Suite 600, Waltham, MA 02451 | www.naveris.com | clinops@naveris.com
US Patents 11,254,989 and 11,168,373 | NavDx-0926-108C/R5